Skip to main content
Premium Trial:

Request an Annual Quote

Claritas Genomics Closes $15M Series B Financing Round

NEW YORK (GenomeWeb) – Claritas Genomics today announced it has secured $15 million in Series B financing.

The Cambridge, Mass.-based pediatric genetic testing services firm said that the funds would be used to expand commercial operations, launch next-generation sequencing-based tests to diagnose pediatric genetic disorders, and build its network of disease experts.

WuXi NextCode Genomics joined Series A investors Boston Children's Hospital, Cincinnati Children's Hospital Medical Center, and Cerner.

In 2013, Claritas won a $9 million contract with the US Department of Veterans Affairs to perform exome sequencing for 19,000 veterans.

Claritas uses the NextCode Health Platform to interpret NGS results. NextCode was acquired by WuXi earlier this month.

"Our work together has the potential to transform children's healthcare, as 40 percent of pediatric disorders are understood to have a clear genetic basis today," Claritas CEO Patrice Milos said in a statement. 

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.